- Home
- HPH vs MNPR Comparison
HPH vs MNPR Comparison
Compare HPH & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPH
- MNPR
- Stock Information
- Founded
- HPH 2010
- MNPR 2014
- Country
- HPH China
- MNPR United States
- Employees
- HPH N/A
- MNPR N/A
- Industry
- HPH
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- HPH
- MNPR Health Care
- Exchange
- HPH NYSE
- MNPR Nasdaq
- Market Cap
- HPH 137.1M
- MNPR 113.5M
- IPO Year
- HPH 2019
- MNPR 2019
- Fundamental
- Price
- HPH $0.27
- MNPR $28.54
- Analyst Decision
- HPH
- MNPR Strong Buy
- Analyst Count
- HPH 0
- MNPR 4
- Target Price
- HPH N/A
- MNPR $38.50
- AVG Volume (30 Days)
- HPH 142.5K
- MNPR 59.4K
- Earning Date
- HPH 01-01-0001
- MNPR 11-08-2024
- Dividend Yield
- HPH N/A
- MNPR N/A
- EPS Growth
- HPH N/A
- MNPR N/A
- EPS
- HPH N/A
- MNPR N/A
- Revenue
- HPH $286,996,105.00
- MNPR N/A
- Revenue This Year
- HPH N/A
- MNPR N/A
- Revenue Next Year
- HPH N/A
- MNPR N/A
- P/E Ratio
- HPH N/A
- MNPR N/A
- Revenue Growth
- HPH 1722.42
- MNPR N/A
- 52 Week Low
- HPH $0.23
- MNPR $1.55
- 52 Week High
- HPH $10.06
- MNPR $38.50
- Technical
- Relative Strength Index (RSI)
- HPH 39.75
- MNPR 60.16
- Support Level
- HPH $0.23
- MNPR $24.00
- Resistance Level
- HPH $0.29
- MNPR $26.52
- Average True Range (ATR)
- HPH 0.05
- MNPR 2.42
- MACD
- HPH -0.00
- MNPR 0.32
- Stochastic Oscillator
- HPH 15.83
- MNPR 68.85
About HPH HIGHEST PERFORMANCE HLDGS INC
Highest Performances Holdings Inc is a financial technology service group based on family financial asset allocation. It focuses on providing personalized wealth management services for emerging middle-class and affluent families, comprehensive support services for financial planners, and diversified financial services for institutional clients.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.